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Abstract
Background: Cystic fibrosis is the most common fatal genetic disorder in the Caucasian population. Scoring systems for
assessment of Cystic fibrosis disease severity have been used for almost 50 years, without being adapted to the milder phenotype
of the disease in the 21st century. The aim of this current project is to develop a new scoring system using a database and
employing various statistical tools. This study protocol reports the development of the statistical tools in order to create such
a scoring system.
Methods: The evaluation is based on the Cystic Fibrosis database from the cohort at the Royal Children's Hospital in
Melbourne. Initially, unsupervised clustering of the all data records was performed using a range of clustering algorithms. In
particular incremental clustering algorithms were used. The clusters obtained were characterised using rules from decision trees
and the results examined by clinicians. In order to obtain a clearer definition of classes expert opinion of each individual's clinical
severity was sought. After data preparation including expert-opinion of an individual's clinical severity on a 3 point-scale (mild,
moderate and severe disease), two multivariate techniques were used throughout the analysis to establish a method that would
have a better success in feature selection and model derivation: 'Canonical Analysis of Principal Coordinates' and 'Linear
Discriminant Analysis'. A 3-step procedure was performed with (1) selection of features, (2) extracting 5 severity classes out of
a 3 severity class as defined per expert-opinion and (3) establishment of calibration datasets.
Results: (1) Feature selection: CAP has a more effective "modelling" focus than DA.
(2) Extraction of 5 severity classes: after variables were identified as important in discriminating contiguous CF severity groups
on the 3-point scale as mild/moderate and moderate/severe, Discriminant Function (DF) was used to determine the new groups
mild, intermediate moderate, moderate, intermediate severe and severe disease. (3) Generated confusion tables showed a
misclassification rate of 19.1% for males and 16.5% for females, with a majority of misallocations into adjacent severity classes
particularly for males.
Conclusion: Our preliminary data show that using CAP for detection of selection features and Linear DA to derive the actual
model in a CF database might be helpful in developing a scoring system. However, there are several limitations, particularly more
data entry points are needed to finalize a score and the statistical tools have further to be refined and validated, with re-running
the statistical methods in the larger dataset.
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Cystic fibrosis (CF) is the most common fatal genetic dis-
order in the Caucasian population, with a carrier rate of
approximately five percent and an annual incidence of
one in 2,500 live births [1]. This autosomal recessive dis-
order is caused by mutations in a single gene located on
chromosome 7, which encodes for the cystic fibrosis
transmembrane regulator protein (CFTR). More than
1500 different mutations have been identified [2]. Abnor-
malities in the CFTR leads to decreased chloride secretion
and increased sodium absorption in these cells, resulting
in dehydration of the airways surface layer and subse-
quent viscous tenacious mucus.
CF is a multi-system disease with a wide variability in the
severity of symptoms and consequently the progression of
the disease. Primarily it is the lungs and pancreas that are
affected, with the small airways of the lungs and the pan-
creatic ducts being obstructed with the viscous tenacious
mucus. This then often results in chronic lung disease and
insufficient function of the exocrine pancreas. Despite the
life expectancy increasing, where the median survival rates
are now exceeding 30 years of age, [1] CF remains an
incurable illness with over 90 percent of the deaths attrib-
uted to lung failure and its associated complications.
Scoring systems for assessment of CF illness severity have
been used for almost 50 years, with the first clinical score
published by Shwachman and Kulczycki in 1958 (SK-
score) [3]. A numerical classification of CF individuals
according to their score launched a more uniform assess-
ment and contributed essentially towards better care and
success of clinical trials [4]. A recent detailed review of
scoring systems (exclusive radiological scores) from our
group highlighted problems associated with the current
systems available, particularly with the most widely used
SK-score [5]. But despite controversial opinions regarding
the use of scoring systems, there seems to be an ongoing
demand for a system to assess the phenotype of this het-
erogenic disease for inter-individual comparison and
intra-individual longitudinal follow up [5]. In particular,
a validated system as a uniform outcome measure allow
meaningful comparison between studies, hence giving the
physician the possibility to classify the patients accord-
ingly to a score. The underlying goal of our present
research is to develop such a new scoring system, taking
into account items regularly and repetitive assessed at the
patient's visit inclusive non-respiratory issues such as
nutrition and bacterial colonisation, and reflecting the
broad spectrum from mild to severe disease status of chil-
dren and adolescents with CF. The advantage of an vali-
dated scoring system over purely radiological scoring
system as those using High Resolution Computer Tomog-
raphy (HRCT) [6] or even hyperpolarized gas MRI [7] is
that it can be used currently by all centres caring for
patients with CF. Once statistical tools are established,
combined scoring systems with for example clinical items
and radiological items can be further developed.
We present in this work the development of statistical
tools to create such a scoring system using database infor-
mation.
Methods
The diagnosis of CF in individuals in the cohort at the
Royal Children's Hospital Melbourne, Australia, is made
according to published guidelines [1], with approximately
90% of individuals diagnosed by the new born screening
program [8]. The CF cohort at the Royal Children's Hospi-
tal represents over 90% of the children in the state of Vic-
toria with a diagnosis of CF [9].
Demographic factors and clinical data as well as pulmo-
nary function and bacterial data of all CF individuals in
our cohort are recorded in the Australasian CF registry
[8,10]. The main data groupings were categorised in either
continuous interval data such as the pulmonary function
values, height and weight, number of outpatient visits and
days hospitalised, or as binary data such as sputum cul-
tures, complications and antibiotics. Approval for this
study was obtained from the Ethics Committee of the
Royal Children's Hospital Melbourne, Australia.
1. Pre-processing of data and initial approach
All data for the years 1999 – 2003 of all individuals from
our cohort were extracted. A data cleaning process then
followed, including normalisation of lung function
parameters (FEV1 = forced expiratory volume in 1 second,
FVC = forced vital capacity and FEF = forced expiratory
flow) for sex, age and height, expressed as percent pre-
dicted. In addition, body mass index was calculated from
weight and height (body mass index = weight in kilo-
grams divided by the square of height in meters) and
expressed as percentiles (BMIPCT) using the Centre of
Disease Control growth charts for the United States [11].
Initially an unsupervised approach was taken to gain
understanding of the groups that may be naturally formed
by the data. At this stage the clustering was performed on
records rather than individuals. Three clustering algo-
rithms were used: k-means, Kohonen self organising maps
[12] and an incremental optimization based clustering
algorithm [13]. The incremental algorithm can be applied
without pre-specifying a number or nature of clusters.
This algorithm produced 5 clusters for the whole data set
but tended to produce 4 clusters for males and 3 for
females. There was general agreement between the clusters
produced using the different algorithms. Decision trees
based on C4.5 [14] were used to give rule descriptions of
the clusters and these were examined by clinical experts.Page 2 of 11
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a clear way of relating the clusters to a measure of CF
severity without going back to knowledge of the individu-
als. So expert clinical opinion on individuals was
obtained and this then allowed a supervised approach to
be adopted.
2. Data preparation
We decided to utilise, during the learning period of devel-
oping the statistical methods, only data of individuals
with pulmonary function tests (PFT) in the dataset, as
PFT's play an important and well recognized role in the
clinical assessment of CF [15]. Performing a PFT does
require some compliance and therefore is age dependent,
therefore the dataset analysis only included children
above the age of 6 years. The last complete entry in the
database was considered in the analysis.
Range standardization (each value within a variable is
divided by that variable's range) was performed to ensure
that variables measured on a larger scale did not unduly
dominate the analysis (see below). All binary variables
(e.g. 0/1) with > 95% zeros were excluded to achieve a
representative dataset with a substantial number of indi-
viduals exhibiting the true condition.
The individual's designated paediatric respiratory physi-
cian estimated the individual's severity, using a 3-point
scale (mild, moderate and severe disease).
A preliminary analysis revealed differences between males
and females in terms of how items vary and correlate, con-
sequently separate models were derived to predict male
and female CF severity.
3. Statistical analysis and technique
Two multivariate techniques were used throughout the
analysis to establish the method with better success in fea-
ture selection and model derivation: 'Canonical Analysis
of Principal Coordinates' (CAP) [16] and 'Linear Discri-
minant Analysis' (DA) [17]. CAP is a constrained factor
analysis method, which attempts to find new axes, based
on a linear combination of the original variables, most
associated with specified factors or covariates (unlike a
unconstrained factor analysis which just tries to explain
differences between individuals). CAP, unlike DA, can
also account for the ordinality of factors and allows the
specification of different measures of inter-individual dis-
similarity. In contrast, DA is restricted to measuring fac-
tors on a nominal scale and the Manhalanobis
dissimilarity coefficient forms an implicit part of this tech-
nique. Preliminary analysis revealed that accounting for
the ordinal nature of CF severity class (using CAP) lead to
higher misclassification rates than if CF severity was con-
sidered on a nominal measurement scale (using DA). In
the current study, DA is used to determine which variables
discriminate between two or more naturally occurring
groups.
A 3-step procedure was performed:
(1). Selection of features to identify the variables most
associated with changes in the 3-scale severity member-
ship. This was performed by a stepwise procedure of dis-
criminant analysis and also through a process of
progressive single feature elimination using optimisation
based classifiers. Each feature was eliminated and the
effect on classification noted. Only those features that had
a substantial effect on classification were retained and the
others were identified as candidates for discarding. The
list of potentially discardable features agreed with those
discarded through the stepwise discriminant analysis
process.
(2). Extraction of 5 severity classes out of the 3 expert-
opinion severity classes applying Linear DA. As a clinical
scale should preferably consist of between 5 and 7 points
[18], we have chosen 5 points as it allows to classify
patients into groups called "mild", "intermediate moder-
ate", "moderate", "intermediate severe" and "severe".
(3.) Training discriminant functions based on the calibra-
tion datasets. This involved two separate Discriminant
Analyses: One used to discriminate between mild and
moderate cases CF (as classified by clinician); and the
other to discriminate between moderate and severe cases.
As both of these analyses were two group discriminant
analyses, linear discriminant functions were used for clas-
sification.
All statistical analyses were conducted using the R (ver-
sion 2.2) statistics package. Optimization based
approaches, developed at the University of Ballarat, Victo-
ria, Australia [19], were also used for feature selection.
4. Validation attempt on test dataset
In a final step, we attempted to validate the derived mod-
els on a different dataset from individuals from the CF
unit at the Royal Children's Hospital Brisbane, Queens-
land. The data were again extracted from the Australasian
CF registry and prepared as described in paragraph 2.
Results
The sample size of the last complete data entry set
included 115 males and 97 females with an age range
between 6 and 21 years.
(1) Feature selection: CAP has a more effective "model-
ling" focus than DA (data not shown), as it was able to
identify the contributing variables (Table 1). Variables notPage 3 of 11
(page number not for citation purposes)
BMC Medical Informatics and Decision Making 2008, 8:44 http://www.biomedcentral.com/1472-6947/8/44considered by CAP as important in differentiating
between CF severities on the 3-point scale were excluded
from further analysis. The optimization based approaches
resulted in substantial agreement with the variables iden-
tified by CAP.
(2) Extraction of 5 severity classes: Variables were identi-
fied as important in discriminating contiguous CF severity
groups on the 3-point scale as mild/moderate and moder-
ate/severe (Figure 1). For all individuals in the relevant
group (e.g. mild and moderate in the first instance); their
value was calculated on the appropriate Discriminant
Function (DF) to determine whether they occupy the bot-
tom, middle or upper third of the DF (Figure 2). DF1 (the
function separating the original mild and moderate
groups) was used to derive the three new groups mild,
intermediate moderate and moderate; and DF2 (that sep-
arating the original moderate and severe groups) to derive
the three new groups moderate, intermediate severe and
severe. As both analyses contained the moderate group,
disagreement between the two discriminant analyses was
possible. Hence, posterior probabilities of the individual
observations were used to choose which groups the indi-
viduals should occupy.
(3) Discriminant functions were trained based on calibra-
tion datasets for both males and females and the resulting
confusion tables generated (Table 2). As a result, a mis-
classification rate of 19.1% for males and 16.5% for
females was identified, with a majority of misallocations
Linear Discriminant Analysis in contiguous 3 severity groupsFigu e 1
Linear Discriminant Analysis in contiguous 3 severity groups. (O = Mild; Δ = Moderate; + = Severe). DA was used to 
derive the direction in space (a vector), associated with the difference between the groups. DF 1 for mild vs moderate and DF 
2 for moderate vs severe. Note: Circles represent regions where each groups mean can be found. The size of the circle indi-
cates each group's variability.
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files of predicted severity groups for both males (Figure 3,
4, 5) and females (Figure 6, 7, 8) were drawn. For males,
22 of the 28 selected variables are correlated with the
signed severity classes (eg patients with milder disease are
less frequent positive for Pseudomonas aeruginosa {CULT
12 & 13}. For females, 23 of the 28 selected variables
reflect disease severity (eg patients with more severe dis-
ease have worse pulmonary function tests.) { FEV1P,
FVCP, FEFP}
Validation attempt on test dataset: The misclassification
rate was substantially higher with a correct classification
in only 34% of males and 23% of females (data not
shown).
From 3 to 5 severity groupsigure 2
From 3 to 5 severity groups. The regions for the three new classes (derived from the original two classes, e.g. mild vs mod-
erate) are chosen such that the number of patients in each group is approximately equal.
 
 
 
Profiles of predicted severity groups (Set 1 males)Figure 3
Profiles of predicted severity groups (Set 1 males). The proportion on the Y-axis indicates percent of subjects having 
that condition in each of the 5 predicted severity groups.
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We present preliminary data for derivation of a scoring
system using statistical techniques applied to a CF data-
base. The aim of the present study protocol was to develop
statistical methods most likely to be valuable in construc-
tion of a scoring system in CF taking into account items
regularly and repetitive assessed in all centres caring for
patients with cystic fibrosis. The initial unsupervised
approach identified a need for an association between
classes and CF measure but also suggested that a 5 point
scale would be more effective with this data than a finer
resolution scale.
A supervised approach was therefore chosen, using CAP
and DA in those individuals old enough to perform PFT.
The inclusion of PFT parameters in a test dataset was
important due to FEV1 being an fairly objective and easily
to obtain measurement to assess clinical CF severity and/
or improvement in clinical trials. Furthermore, PFT plays
a key role in validating a scoring system. BMIPCT as an
assessment of therelative proportion of weight for height
was introduced, as the percentage of ideal body weight
underestimates the severity of malnutrition in CF-chil-
dren with short stature, whilst overestimating the severity
of malnutrition in CF children with tall stature [20].
Throughout the whole analysis, two different statistical
methods were used to establish the method with better
success: CAP and DA. CAP was used even though it is a
multivariate technique very similar to DA as it offers three
main advantages:
(1) CAP attempts to detect differences between groups,
rather than focusing on how to differentiate between
groups (even though mathematically these operations are
very similar, the focus of the results is different). (2) DA
uses a Manhalanobis measure to differentiate between
subjects. In the absence of data preprocessing, variables of
a larger magnitude can dominate the analysis (this was
another reason we range standardized the data prior to
discriminant analysis). In contrast, CAP is not restricted to
a particular measure of between-patient differences; there-
fore it is a much more general technique.
(3) CAP can also account for the ordinal progression of CF
severity (i.e. it recognizes the natural order of moving
from mild to severe). DA does not recognize the ordinal
nature of CF severity class and only considers classes (e.g.
severity) on a nominal scale.
The application of CAP was superior to DA in derivation
of feature selection; it has a more specific "modeling"
focus then DA. In this respect identifying the "contribut-
ing variables" is more sensible with CAP than DA. For this
to be done with DA, would take a model selection
approach to rule out (backwards) or include (forwards)
variables. CAP is also more amenable to a graphical repre-
sentation of the multivariate data. In deriving a model
which acknowledged the progressive nature of severity,
DA produced lower misclassification rates.
The variables that contribute to predicting severity do not
vary with gender. The relative importance (weighting) of
Profiles of predicted severity groups (Set 2 males)Figure 4
Profiles of predicted severity groups (Set 2 males). The proportion on the Y-axis indicates percent of subjects having 
that condition in each of the 5 predicted severity groups.Page 6 of 11
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males and females. This may possibly reflect the docu-
mented clinical gender differences, where females with CF
have been shown across age strata to have a shorter life
expectancy [21].
For the calibration dataset, severity classification was
accurate for 81% of males and 83% of females, with most
of the misallocations into adjacent severity classes. This
was encouraging, but unfortunately not repeatable with
the test dataset from the Queensland CF unit at the Royal
Children's Hospital in Brisbane. One explanation for this
constellation might be the small number of individuals
(32 in total) in the test dataset, augmented by different
treatment strategies and therapeutic approaches between
the two centres. Another reason might be that there are
actual differences between the calibration (Melbourne)
and test (Brisbane) populations, or that measurement
and/or treatment protocols vary at the two locations.
A problem in general is that each level or type of therapy
is confounded with severity. When individuals get to a cer-
tain level of severity, various treatments are prescribed. A
canonical analysis model including a temporal (repeated
measure) component might help to partition and evalu-
ate the effect of treatment.
There are several limitations of this study. One of the
main limitation is the number of data entries, where vari-
ables may have been excluded due to too few subjects
exhibiting a certain symptom. In addition, the variables
identified by CAP may not be the only variables that
might be useful for determining CF severity, and that
larger samples may identify these additional variables.
There also may be other possible explanatory variables
that may not have been measured or included in the CF
database.
After the initial unsupervised approach failed it was neces-
sary to seek expert clinical opinion on individuals illness
severity. An expert opinion is in a way subjective and may
not necessarily reflect the real disease severity. Although a
clinical scale should preferably consist of between 5 and 7
points [18], to minimize the subjective impact, there was
only a classification for the experts into the three groups
mild, moderate and severe possible. We then further
extracted the preferred 5 groups from the 3 groups (Fig 2)
using Linear DA, but this might be one of the reasons the
Profiles of predicted severity groups for quantitative variables (males)Figure 5
Profiles of predicted severity groups for quantitative variables (males). Mean value for quantitative variables associ-
ated with each of the CF severity group.
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was chosen as both of these analyses, the discrimination
between mild and moderate and between moderate and
severe cases, were two group discriminant analyses. In
addition, using the extracted 5 groups, derived from the
original 3 groups of "subjective" expert opinion, as "true"
classification for construction of the confusion tables
(Table 2), might have problems.
Another main limitation is the lack of validation employ-
ing imaging techniques, particularly CT scanning. We
have elected not to include radiological aspects into the
scoring systems we have explored for several reasons.
While some earlier scoring systems did included measure-
ments derived from plain chest X-rays, it is now well
established that this form of imaging is an insensitive way
of detecting early or mild disease. Nowadays, CT scanning
of the lung however has been shown to be significantly
more sensitive in detecting early changes of lung disease
than plain chest imaging or PFT's [22]. At this stage how-
ever CT scanning is not routinely used clinically as an
assessment tool for detecting early lung disease in CF as
there is a lack of a consensus on the optimal CT scoring
system [23], although it is widely used in research studies
[24]. In addition, there is a lack of consensus as to what
style of CT scanning might be the most appropriate, par-
ticularly to reduce radiation dose [24]. Some of the studies
have used HRCT (in which thin 0.5–1.5-mm slices are
obtained every 0.5, 1, or 2 cm from lung apex to base dur-
ing inspiration) [25], or volumetric scanning (complete
spiral CT imaging covering the entire lung for inspiratory
and expiratory scanning) [25] with some recent evidence
that only performing exspiratory scanning to reduce radi-
ation exposure might be sufficient to monitor progression
of CF disease [26]. Again others are using so called 3 slice
scanning protocols to reduce radiation dose with just 3
slices spaced above the carina, below the carina and just
above the diaphragm [24]. With this ongoing effort to
reduce radiation dose, scanner settings and protocolls will
be further altered with still some way to go before CT
scans can be used routinely clinically. In addition, there is
some emerging evidence that another lung function meas-
urement than PFT's, the lung clearance index by multiple-
breath inert gas wash out, may be even more sensitive
than HRCT scanning for detecting early lung involvement
in CF [27]. This has led us to decide not to include CT
scanning in our scoring system. We feel that at this stage it
is appropriate to exclude CT scanning as part of any scor-
ing systems. Once fully established, CT scoring may well
be a useful addition to future clinical scores, and we agree
that this factor then should be included.
Conclusion
Our preliminary data show that using CAP for detection
of selection features and DA to derive the actual model in
a CF database is promising for developing a scoring sys-
Profiles of predicted severity groups (Set 1 females)Figure 6
Profiles of predicted severity groups (Set 1 females). The proportion on the Y-axis indicates percent of subjects having 
that condition in each of the 5 predicted severity groups.
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tistical tools have further to be refined and validated in
datasets of other centres. For this, we will seek access to
additional data from other large cohorts such as the Aus-
tralasian CF registry. Once a scoring system has been final-
ized then it will need to be clinically assessed with regard
to intra- and inter-observer reliability, and combined scor-
ing systems with for example clinical items and radiolog-
ical items can be further developed.
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